Table 1.
Features of the study population
| Overall | RA | PsA | AS | P* | |
|---|---|---|---|---|---|
| N = 341 | N = 197 | N = 85 | N = 59 | ||
| Age, years, mean (sd) | 57.6 (13.2) | 61.3 (12.9) | 56.1 (11.3) | 47.7 (11.5) | < 0.01 |
| Male, n (%) | 127 (37.2) | 40 (20.3) | 49 (57.7) | 38 (64.4) | < 0.01 |
| GCs ≥ 7.5 mg per day, n (%) | 17 (5.0) | 16 (8.1) | 1 (1.2) | 0 (0) | < 0.01 |
| csDMARDs, n (%) | 112 (32.8) | ||||
| Methotrexate | 87 (25.5) | 65 (33.0) | 20 (23.5) | 2 (3.4) | < 0.01 |
| Others | 32 (9.4) | 24 (12.2) | 4 (4.7) | 4 (6.8) | 0.124 |
| s | |||||
| TNFi | 232 68.0) | 115 (57.8) | 63 (74.1) | 54 (91.5) | < 0.01 |
| Anti-IL6 | 33 (9.7) | 33 (16.6) | 0 (0) | 0 (0) | < 0.01 |
| Anti-IL1 | 4 (1.2) | 4 (2.0) | 0 (0) | 0 (0) | < 0.01 |
| Anti-CTLA4 | 38 (11.4) | 38 (19.1) | 0 (0) | 0 (0) | < 0.01 |
| JAKi | 7 (2.1) | 7 (3.5) | 0 (0) | 0 (0) | < 0.01 |
| Anti-IL17 | 21 (6.2) | 0 (0) | 16 (18.8) | 5 (8.5) | < 0.01 |
| Anti-PDE4 | 6 (1.8) | 0 (0) | 6 (7.1) | 0 (0) | < 0.01 |
| At least 1 visit performed, n (%) | 119 (34.9) | 76 (38.6) | 28 (32.9) | 15 (25.4) | 0.19 |
GCs glucocorticoids, csDMARDs conventional synthetic disease-modifying anti-rheumatic drug, bDMARDs biologic disease-modifying anti-rheumatic drug, Anti-IL6 Anti-interleukin 6, Anti-IL1 Anti-interleukin 1, Anti-CTLA4 Anti-Cytotoxic T-Lymphocyte Antigen 4, JAKi Janus kinase 1 inhibitor, Anti-IL17 Anti-interleukin 17, Anti-PDE4 Anti-phosphodiesterase-4, RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing spondylitis
*Pearson chi-square test